Related Experiment Video

Updated: Feb 24, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System

Reda Biomy1, Mohamed Abdelshafy2, Ahmed Abdelmonem2

  • 1Faculty of Medicine, Kafrelsheikh University, Kafr El-Sheikh, Egypt.

Clinical Medicine Insights. Cardiology
|August 15, 2017
PubMed

Insights

Direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) showed no significant cardiovascular effects in Egyptian patients. This study confirms the safety of DAAs in managing HCV, even with high prevalence.

Area of Science:

  • Hepatology
  • Cardiology
  • Virology

Background:

  • Hepatitis C virus (HCV) infection poses a significant public health challenge in Egypt.
  • Direct-acting antiviral agents (DAAs) offer a promising treatment for HCV.

Purpose of the Study:

  • To evaluate the cardiovascular impact of DAAs in patients with HCV.
  • To assess potential cardiac adverse events associated with DAA therapy.

Main Methods:

  • 170 HCV patients received either triple (pegylated interferon alfa, sofosbuvir, ribavirin) or dual (sofosbuvir, simeprevir) DAA therapy.
  • Cardiovascular assessments included medical history, clinical exams, ECG, echo-Doppler, and lab tests over 6-12 months.
  • Primary endpoint was the occurrence of major cardiovascular events.

Main Results:

  • No major cardiovascular events were observed in either treatment group.
  • No significant changes in ECG parameters (ST-T wave, arrhythmias, QT interval) were noted.
  • Echocardiographic parameters, including regional wall motion, systolic, and diastolic functions, remained stable.

Conclusions:

  • Combined oral DAAs, with or without interferon, do not significantly impact the cardiovascular system in HCV patients.
  • DAA therapy is safe concerning cardiovascular effects in this patient population.
  • Further research may explore long-term cardiovascular outcomes.
Abstract

Keywords:
Hepatitis C virusechocardiographyoral direct antiviral agents

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.2K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
294
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
243
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
312
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
266
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
482
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K